Form 4: Amylyx Pharmaceuticals Executive Camille L. Bedrosian Reports Acquisition of Shares and Stock Options

Chief Medical Officer Camille L. Bedrosian reports acquisition of common stock and stock options in Amylyx Pharmaceuticals.

Summary

• Camille L. Bedrosian, Chief Medical Officer of Amylyx Pharmaceuticals, reported acquiring 96,910 shares of common stock on April 16, 2024, through a restricted stock unit (RSU) award.
• The RSUs vest in three tranches: 33% on September 30, 2024, 33% on March 31, 2025, and 34% on September 30, 2025, contingent upon continued service.
• Bedrosian also acquired stock options for 120,000 shares at an exercise price of $2.01 on the same date.
• These options vest with 25% becoming exercisable on April 16, 2025, and the remainder vesting monthly over the subsequent 36 months, also subject to continued service.
• Following these transactions, Bedrosian directly owns 155,243 shares of common stock and holds options for 120,000 shares.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard disclosure of insider transactions. The acquisition of shares and options could be interpreted as a slightly positive signal, but it's not definitively bullish.

Positives

• The acquisition of shares and options by a key executive could be seen as a positive signal regarding their confidence in the company's future.

Future Outlook

The vesting schedules for both the RSUs and stock options are contingent upon the Reporting Person's continued service to the Issuer.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the ownership positions of company executives.

Stakeholder Impact

• Shareholders may view the executive's increased stake in the company positively.

Key Dates